UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, extending its presence in T-cell engager (TCE) antibodies for autoimmune and inflammatory indications. The deal adds Candid’s lead asset, cizutamig, a BCMA x CD3 bispecific designed to target plasma cells and B cells while aiming to manage cytokine release. Candid’s pipeline also includes additional Phase I programs and IND-enabling candidates. The transaction positions UCB to add China-derived autoimmune assets into its broader immunology strategy and keep building next-generation TCE capabilities.